# Noom's GLP-1Rx Program Combines Medication with Behavioral Support for Weight Loss
Noom has launched GLP-1Rx, a program pairing glucagon-like peptide-1 receptor agonist medications with its established behavioral coaching model. The service delivers prescription GLP-1 drugs alongside the app-based psychology and nutrition framework Noom already offers.
GLP-1 medications like semaglutide and tirzepatide work by slowing digestion and increasing satiety signals to the brain. They've become popular for weight management, but they work best alongside sustained lifestyle changes. Noom's approach acknowledges this reality. The program pairs pharmaceutical intervention with behavioral coaching, addressing both the physiological and psychological sides of weight regulation.
The model reflects what weight loss research shows: medication alone doesn't guarantee lasting results. People often regain weight when they stop taking GLP-1s without addressing eating patterns and habits. Noom's existing platform focuses on cognitive behavioral techniques, food logging, and habit formation. Adding medication access creates a more complete treatment package.
Noom positions GLP-1Rx as "clinically-backed" and "customized," suggesting personalized dosing and medical oversight. This matters because GLP-1 medications require prescriber monitoring. They carry side effects including nausea and, rarely, thyroid concerns. Having clinical oversight built into an app-based program could improve medication safety and adherence.
The service targets people who struggled with weight loss through diet and exercise alone. For some, GLP-1 medications genuinely help. For others, the appetite suppression creates space to retrain eating habits more effectively than willpower alone allows.
The real test comes later. Whether people maintain weight loss after stopping medication depends on whether the behavioral changes stick. Noom's track record on long-term outcomes